✦ LIBER ✦

Subcutaneous heparin treatment increases survival in small cell lung cancer

✍ Scribed by Bernard Lebeau; Claude Chastang; Jeanne-Marie Brechot; Frédérique Capron; Berteand Dautzenberg; Corinne Delaisements; Michel Mornet; Janine Brun; Jean-Paul Hurdebourcq; Etienne Lemarie

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 685 KB
Volume: 74
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19940701)74:1<38::aid-cncr2820740108>3.0.co;2-e

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Small cell lung cancer: Analysis of trea

Small cell lung cancer: Analysis of treatment factors contributing to prolonged survival

✍ Dr. R. Catane; A. Lichter; Y. J. Lee; Dr. H. D. Brereton; J. G. Schwade; E. Glat 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 610 KB

## Seventy -one consecutive patients with small cell lung cancer (SCLC) were treated in the Radiation Oncology Branch of the National Cancer Institute using six different radiation regimens in combination with cyclophosphamide, vincristine and doxorubicin chemotherapy. Patients treated with concur

Treatment of small-cell lung cancer in e

Treatment of small-cell lung cancer in elderly patients

✍ Athanasios G. Pallis; Frances A. Shepherd; Denis Lacombe; Cesare Gridelli 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

Vorinostat increases carboplatin and pac

Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells

✍ Taofeek K. Owonikoko; Suresh S. Ramalingam; Beatriz Kanterewicz; Trent E. Balius 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 533 KB

## Abstract We observed a 53% response rate in non‐small cell lung cancer (NSCLC) patients treated with vorinostat plus paclitaxel/carboplatin in a Phase I trial. Studies were undertaken to investigate the mechanism (s) underlying this activity. Growth inhibition was assessed in NSCLC cells by MTT

Predictors of 5-year survival and curabi

Predictors of 5-year survival and curability in small cell lung cancer

✍ J. P. A. Crown; A. Phillippe Chahinian; I. S. Jaffrey; O. J. Glidewell; M. Kanek 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 477 KB 👁 2 views

EGFR inhibition in the treatment of non-

EGFR inhibition in the treatment of non-small cell lung cancer

✍ David E. Gerber 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

MDM2 SNP309 contributes to non-small cel

MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese

✍ Jing Dong; Binhui Ren; Zhibin Hu; Jiaping Chen; Lingmin Hu; Juncheng Dai; Guangf 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract Murine double minute 2 (MDM2) is a negative regulator of the tumor suppressor gene __p53__. Single nucleotide polymorphisms in __MDM2__ and __p53__ can affect patient's response to chemotherapy as well as overall survival of many cancers. This study aimed to assess the associations betw